Le Lézard
Classified in: Health
Subjects: NPT, TRI

UsAgainstAlzheimer's Statement on Alzheimer's Drug Development


WASHINGTON, May 22, 2018 /PRNewswire-USNewswire/ -- UsAgainstAlzheimer's Chairman George Vradenburg today issued the following statement regarding the termination of clinical trial testing of the Alzheimer's drug atabecestat by Janssen:

"To each individual who participated in the atabecestat study and to their families and caregivers also impacted by the disease: thank you for your courage and dedication to finding a cure for Alzheimer's disease. Though you are surely disappointed, as we are, you should feel reassured that your efforts have contributed to a greater understanding of the fundamental science underlying Alzheimer's disease. Regardless of the outcome, this study and each person involved has played a critical role in building the knowledge we need to one day cure this complex disease. Each successive clinical trial teaches us more about Alzheimer's, and provides us with data that will inform the development of future drugs. Without your willingness to participate in research, and without the perseverance of companies like Janssen, we would be much farther away from a cure.

Thank you, Janssen, for your commitment to curing a disease that impacts almost 6 million people in the U.S. and more than 50 million worldwide. Your continued effort to find a cure amidst the growing number of drug failures and the rising costs of research and development gives hope to and shows compassion for the millions living with the disease and their hardworking caregivers. What we have learned through the atabecestat study, along with your future work, will accelerate progress towards treatments and a cure."

Connect with UsAgainstAlzheimer's.
Learn about UsA2's work around the globe through our social channels:

https://twitter.com/UsAgainstAlz   
https://www.usagainstalzheimers.org/  
https://www.facebook.com/UsAgainstAlz/         

Founded in 2010, UsAgainstAlzheimer's (UsA2) is an innovative non-profit organization demanding ? and delivering ? a solution to Alzheimer's. Driven by the suffering of millions of families, UsAgainstAlzheimer's presses for greater urgency from government, industry and the scientific community in the quest for an Alzheimer's cure ? accomplishing this through effective leadership, collaborative advocacy, and strategic investments.

Contact Melissa Green 202.429.4940 | [email protected]

SOURCE UsAgainstAlzheimer's


These press releases may also interest you

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....



News published on and distributed by: